CRISPR/Cas9-Engineered HLA-Deleted Glomerular Endothelial Cells as a Tool to Predict Pathogenic Non-HLA Antibodies in Kidney Transplant Recipients

The authors designed a non-human leukocyte antigen (HLA) antibody detection immunoassay using HLA class I and II–deficient glomerular endothelial cells that had been previously generated through CRISPR/Cas9-induced B2M and CIITA gene disruption.